Trial Profile

A phase 1/2 study to evaluate the safety, tolerability, and preliminary efficacy of combining pimasertib with DAY101 in patients ≥12 years of age with recurrent, progressive, or refractory solid tumors with MAPK pathway aberrations

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 06 Dec 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

22 Nov 2021 According to a Day One Biopharmaceuticals media release, company expects to initiate a Phase 1b combination portion of the study with pimasertib, in the first quarter of 2022.
25 Feb 2021 New trial record
23 Feb 2021 According to a Day One Biopharmaceuticals media release, the company has collaborated with the Merck KGaA for the combination study. The company looks forward to initiate this study later in this year 2021.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com